Integrating U=U Into HIV Counseling in South Africa
- Sponsor
- Boston University
- Study ID
- NCT04504357
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Tablet based U=U app — BEHAVIORALTablet based "app" focusing on TasP/U=U videos on: a) the science of TasP/U=U including risks, (b) benefits to self (e.g. psychological benefits, ability to have children), (c) benefits to partners (e.g. secondary prevention), (d) benefits to society (e.g. AIDS-free generation), and (e) TasP self-efficacy, including viral load (VL) literacy, disclosure, and couples testing.
- Text messages — OTHERMonthly text messages reinforcing intervention content
Study Details
The near-elimination of HIV transmission with antiretroviral therapy (ART) has provided the world with a clear path to end the HIV epidemic through the mass provision of ART at diagnosis, i.e. test-and-treat. Despite the substantial prevention benefits of ART, the investigators found minimal knowledge of treatment-as-prevention (TasP) in two population-based surveys recently conducted in South Africa. In addition, current public health messaging and clinical HIV counselling in South Africa do not emphasize the prevention benefits of ART. In this formative research study the investigators developed an app-based educational video intervention that provides information on Undetectable = Untransmittable (U=U) that is locally-appropriate and can be integrated into routine HIV counselling. The intervention was be piloted in a clinical trial of patients in South Africa receiving HIV post-test and adherence counselling services, to determine feasibility and acceptability, impact on U=U knowledge and attitudes, impact on stigma and psychological well being, and preliminary evidence for ART uptake and adherence. The study builds on a longstanding collaboration between Boston University and the Health Economics and Epidemiology Research Office (HE2RO) at the University of Witwatersrand in Johannesburg, South Africa. The study is highly innovative because the investigators take a novel approach - disseminating information on the prevention benefits of ART - to improve the wellbeing of people living with HIV (PLWH) and motivate early uptake of ART in South Africa. The investigators hypothesized that disseminating information about U=U and treatment-as-prevention could increase ART adherence, retention, and viral suppression, enabling countries to maximize the impact of test-and-treat.
Key Dates
- Start date
- Nov 21, 2022
- Status verified
- Aug 2025
- Primary completion
- Feb 15, 2024
- Completion
- Feb 15, 2024
Study Design
- Enrollment
- 135 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- PREVENTION
Arms
- No Intervention: Arm A- No interventionParticipants randomized to Arm A received no research intervention.
- Experimental: Arm B- "Undetectable & You" AppParticipants randomized to Arm B interacted with "Undetectable \& You" a tablet-based treatment literacy App that shared the science of U=U through testimonials of PLHIV and their partners. Participants in Arm B also received monthly text messages related to the themes of the App.
Primary Outcome Measure
Documented HIV Viral Load <200 Copies/mL at 3-10 Months [ Time Frame: 3-10 months ]
Related Studies
- Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIVRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Washington D.C., District of Columbia
- Viral Load in Blood and Lymph Tissues in People Living With HIVRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
- Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and CancerRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Leukapheresis to Obtain Plasma or Lymphocytes for Studies of HIV-infected Patients, Including Long-term Non-progressorsRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland